All In Biotech

Drug Trial Radar · NCT07520006

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

An Open-label, Multicenter Phase 1b/2 Study to Evaluate the Safety and Efficacy of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Sep 30, 2026

Primary completion

May 2033

Study completion May 2033

Sponsor

Lead sponsor
Nurix Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Apr 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Conditions

  • B-cell Lymphoma
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Interventions

  • NX-5948Drug

    Administered orally once daily as a capsule

  • venetoclaxDrug

    Administered orally once daily as a tablet per prescribing information

  • rituximabDrug

    Administered as an intravenous (IV) infusion per prescribing information

  • obinutuzumabDrug

    Administered as an IV infusion per prescribing information

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-emergent adverse eventsTime frame: Up to approximately 7 years

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope Orange County Lennar Foundation Cancer Center

    Irvine, California · Not yet recruiting

  • Rocky Mountain Cancer Centers

    Aurora, Colorado · Recruiting

  • University of Miami

    Coral Gables, Florida · Not yet recruiting

  • University of Kansas Cancer Center

    Kansas City, Kansas · Not yet recruiting

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada · Not yet recruiting

  • New Jersey Cancer Care

    Belleville, New Jersey · Not yet recruiting

  • Oncology Associates of Oregon

    Eugene, Oregon · Recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • Texas Oncology - Northeast

    Tyler, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.